AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31087715
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for respiratory infections
Trial: 31087715
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for urinary tract infections
Trial: 31087715
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for skin and soft tissue infections
Trial: 31087715
Drug: Beta-lactamase sensitive
RxNorm normalized name: Beta-lactamase sensitive penicillins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactamase sensitive penicillin (more than two prescriptions)
Trial: 27648792
Drug: Ice/gel pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice/gel pack cryotherapy wrap
Trial: 2098653
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/daily)
Trial: 28248854
Drug: Conventional chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional chest physical therapy (CCPT)
Trial: 25787020
Drug: Losartan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (mean 43 ± 12 mg/day)
Trial: 20160397
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day pioglitazone for 12 weeks
Trial: 20160397
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day metformin for 12 weeks
Trial: 17089155
Drug: Microwave diathermy
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microwave diathermy treatment (passive hyperthermia) increasing muscle temperature to over 40 degrees C, 16-20 hours prior to exercise.
Trial: 30796001
Drug: Polycarbonate groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycarbonate groups (all treatment methods)
Trial: 30796001
Drug: PMMA groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMMA groups (all treatment methods)
Trial: 29020247
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg once daily for 3 days
Trial: 29020247
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) twice daily for 3 days
Trial: 24854088
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (clobetasol propionate 0.05% ointment) applied for the first 2 days, followed by petrolatum jelly for the rest of the week.
Trial: 21729165
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 25 mW/cm2
Trial: 21729165
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 50 mW/cm2
Trial: 21729165
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (5-ALA) PDT at 75 mW/cm2
Trial: 16253380
Drug: Multiple actrapid
RxNorm normalized name: Human Actrapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple actrapid and NPH insulin injections
Trial: 16253380
Drug: Sulphonylurea and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea and metformin+/‐acarbose
Trial: 14967744
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiotherapy (carboplatin 30 mg/m2 on days 1-5 of weeks 1, 3, and 5; radiotherapy 54.0 Gy to all risk volumes plus 10.0 Gy to high-risk volumes; 5 daily fractions of 1.8 Gy each per week)
Trial: 11051743
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (nitrosorbid, cardiket) 80 mg/day
Trial: 11051743
Drug: Isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide 5‐mononitrate (mono mac) 51.5 mg/day
Trial: 8223839
Drug: Controlled-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulation containing metoprolol 100 mg and hydrochlorothiazide 12.5 mg
Trial: 8223839
Drug: Conventional combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combination tablet
Trial: 3532593
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine b.i.d. (49 patients)
Trial: 3532593
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine nocte (47 patients)
Trial: 26524709
Drug: Elevated hsTnT
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated hsTnT (≥14 ng/L)
Trial: 16583831
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/day plus MPA 2.5 mg/day (n = 7)
Trial: 16583831
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (n = 13)
Trial: 7552059
Drug: Empirical titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical titration of electrical stimulus for ECT
Trial: 7552059
Drug: Dose predictive
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose predictive methods from two different ECT equipment instruction manuals
Trial: 2316883
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (3 mg/min)
Trial: 6444861
Drug: Lotion with
RxNorm normalized name: LOTION WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion with hydrocortisone acetate ('Actinac')
Trial: 6444861
Drug: Lotion without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lotion without hydrocortisone acetate
Trial: 30773191
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 3 to 9 ml of iodined PolyEthylene Glycol (PEG) hydrogel
Trial: 31322589
Drug: Elgydium Protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elgydium Protection caries toothpaste used for brushing teeth twice a day for 6 months
Trial: 28683939
Drug: Scoring balloon
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring balloon pre-dilation before drug-coated balloon (DCB) therapy
Trial: 28683939
Drug: Standard DCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DCB therapy
Trial: 23932219
Drug: Multistrain preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistrain preparation of lactobacilli and bifidobacteria (6 × 10^10 organisms, one per day for 21 days)
Trial: 23932219
Drug: Multistrain preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistrain preparation of lactobacilli and bifidobacteria
Trial: 16228108
Drug: Intra-articular tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular tenoxicam 20 mg once weekly for 1-3 weeks
Trial: 16228108
Drug: Oral tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tenoxicam 20 mg/day for 3 weeks
Trial: 9305716
Drug: CsA-based quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-based quadruple induction therapy using an antilymphocyte globulin preparation (ATG)
Trial: 9305716
Drug: CsA-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-based triple therapy
Trial: 9305716
Drug: CsA-based quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-based quadruple induction therapy using an interleukin-2 receptor antibody (BT563)
Trial: 8382131
Drug: Sinorphan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan (100 mg)
Trial: 3532209
Drug: Intracervical Prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Prostaglandin E2 (0.5 mg in 2.5 ml triacetin-gel)
Trial: 27671868
Drug: Double-low imaging
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-low imaging protocol (80-100 kV, 200 mAs, iohexol 300 mg iodine/ml, 1-1.5 ml/kg)
Trial: 27671868
Drug: Conventional CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CT protocol (120 kV, 200-300 mAs, iopamidol 370 mg iodine/ml, 1-1.5 ml/kg)
Trial: 8703882
Drug: Argon green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon green laser treatment (n = 79)
Trial: 8703882
Drug: Krypton red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton red laser treatment (n = 72)
Trial: 2537795
Drug: Captopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (10 mg i.v. bolus followed by 10 mg/hr constant infusion)
Trial: 2537795
Drug: Human ANF
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human ANF (99-126) infusion
Trial: 25347418
Drug: SC +
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC + pharmaceutical medication management
Trial: 22923258
Drug: Dexmedetomidine 0.1
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.1 μg/kg
Trial: 22923258
Drug: Control (Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Dexmedetomidine 0 μg/kg)
Trial: 20940335
Drug: Betahistine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (24 mg b.i.d.)
Trial: 22353021
Drug: Wechsler Adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wechsler Adult Intelligence Scale‐Fourth Edition (WAIS‐IV) administered at baseline and again either 3 or 6 months later
Trial: 9638029
Drug: 75 g.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g.kg‐1 load
Trial: 9638029
Drug: 95 g.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 g.kg‐1 load
Trial: 8032079
Drug: Tamoxifen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (60 mg/die)
Trial: 2574550
Drug: Cetirizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (20 mg QD for two days)
Trial: 2574550
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg BID for 1 week)
Trial: 27895845
Drug: 7-valent conjugate
RxNorm normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent conjugate pneumococcal vaccine
Trial: 22221277
Drug: Comprehensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive intervention that paired behavioral treatment with naltrexone
Trial: 18499110
Drug: Melatonin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (4 mg prolonged release)
Trial: 31493163
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg every 2 weeks
Trial: 28774898
Drug: trabectedin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trabectedin 1.5 mg/m2 as a 24-hour continuous intravenous infusion once every 3 weeks
Trial: 28774898
Drug: dacarbazine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dacarbazine 1,000 mg/m2 i.v. once every 3 weeks
Trial: 21418785
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 25 mg twice weekly
Trial: 17420365
Drug: Intracameral or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral or intravitreal injection of 40 microg of gentamicin sulfate and 45 microg of clindamycin
Trial: 17420365
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: 17420365
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection
Trial: 14633177
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with a daily dose of 5 MU of IFN‐alpha2b for 4 weeks, followed by 5 MU three times a week with ribavirin (1000‐1200 mg/day, according to weight) until completing 1 year of treatment.
Trial: 14633177
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of IFN‐alpha2b of 3 MU three times per week for 48 weeks together with ribavirin (1000‐1200 mg/day, according to weight).
Trial: 14633177
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment in patients with genotype 1 and elevated viral load (>2 x 10(6) copies/ml).
Trial: 14633177
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment compared to standard treatment regarding dropouts and side effects.
Trial: 1550038
Drug: Breakfast treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast treatment (three meals per day)
Trial: 1550038
Drug: No-breakfast treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-breakfast treatment (two meals per day)
Trial: 3993543
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 to 320 mg/day)
Trial: 3993543
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 200 mg/day)
Trial: 25316430
Drug: Polyherbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyherbal formulation (500 mg, twice daily)
Trial: 15784709
Drug: GH by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH by sc injection six times per week (0.30 mg/kg.wk)
Trial: 15784709
Drug: Control (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (C), no GH treatment
Trial: 11840368
Drug: Simvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (5 mg/day, increased to maximum 20 mg/day if non-HDL > 135 mg/dL)
Trial: 27791311
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% solution
Trial: 30944142
Drug: 2% chlorhexidine-alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine-alcohol for skin preparation before catheter insertion
Trial: 30944142
Drug: 5% povidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% povidone iodine-alcohol for skin preparation before catheter insertion
Trial: 24243886
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/d
Trial: 19929371
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for CDI
Trial: 9675657
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment with N-acetyl-cysteine
Trial: 9675657
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment without N-acetyl-cysteine
Trial: 8016036
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 mg), chewed ad libitum
Trial: 2605867
Drug: Triple-hormone combination
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-hormone combination (adrenaline, cortisol, glucagon)
Trial: 22880820
Drug: Thalidomide 100
RxNorm normalized name: thalidomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 100 mg once a day for 14 days
Trial: 8083708
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy and surgical resection
Trial: 8083708
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with > or = 90% necrosis and postoperative chemotherapy
Trial: 8083708
Drug: Poor response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Poor response to preoperative chemotherapy and/or lack of postoperative chemotherapy
Trial: 2572182
Drug: Loratadine 0.11-0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 0.11-0.24 mg/kg once daily
Trial: 2572182
Drug: Dexchlorpheniramine 0.10-0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine 0.10-0.23 mg/kg every 8 hours
Trial: 803831
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with hyperosmolar glucose (10.5 gm nitrogen, 2,340 kilocalories/day)
Trial: 803831
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with hyperosmolar glucose (5.9 gm nitrogen, 1,600 kilocalories/day)
Trial: 30361241
Drug: 8-week once-weekly
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week once-weekly regimen of rifapentine plus isoniazid
Trial: 27473688
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for cannabis cessation (1-hour sessions once a week for 16 weeks, in addition to pharmacological treatment)
Trial: 27473688
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (psychoeducation + pharmacological treatment)
Trial: 15939408
Drug: Testosterone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (0.5 mg)
Trial: 12902802
Drug: Monotherapy postpartum
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy postpartum
Trial: 12902802
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy postpartum
Trial: 12902802
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral therapy postpartum
Trial: 8780817
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) therapy
Trial: 12902802
Drug: Stable therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable therapy
Trial: 1516491
Drug: Beef insulin
RxNorm normalized name: Beef insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef insulin (B)
Trial: 1516491
Drug: Sulfated beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfated beef insulin (SB)
Trial: 1516491
Drug: Pork insulin
RxNorm normalized name: Pork insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork insulin (P)
Trial: 9212308
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (H)
Trial: 2981652
Drug: Metkephamid (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metkephamid (50 mg intramuscularly)
Trial: 7860754
Drug: CD4 binding
RxNorm normalized name: CD4 IgG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 binding site antibodies
Trial: 6127095
Drug: Epoprostenol (PGI2)
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoprostenol (PGI2) 1 and 2 ng/ml
Trial: 6127095
Drug: Atropine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.04 mg/kg i.v.
Trial: 6127095
Drug: Atenolol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 0.2 mg/kg i.v.
Trial: 6127095
Drug: Propranolol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.2 mg/kg i.v.
Trial: 29855175
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg every other week)